These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 23238016)

  • 21. Attacking MALT1 for ABC-DLBCL therapy.
    Krappmann D
    Oncotarget; 2012 Dec; 3(12):1489-90. PubMed ID: 23455231
    [No Abstract]   [Full Text] [Related]  

  • 22. Development of new Malt1 inhibitors and probes.
    Xin BT; Schimmack G; Du Y; Florea BI; van der Marel GA; Driessen C; Krappmann D; Overkleeft HS
    Bioorg Med Chem; 2016 Aug; 24(15):3312-29. PubMed ID: 27085674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
    Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
    Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma.
    Plotnik JP; Richardson AE; Yang H; Rojas E; Bontcheva V; Dowell C; Parsons S; Wilson A; Ravanmehr V; Will C; Jung P; Zhu H; Partha SK; Panchal SC; Mali RS; Kohlhapp FJ; McClure RA; Ramathal CY; George MD; Jhala M; Elsen NL; Qiu W; Judge RA; Pan C; Mastracchio A; Henderson J; Meulbroek JA; Green MR; Pappano WN
    Mol Cancer Ther; 2024 Jul; 23(7):949-960. PubMed ID: 38507740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.
    Cheng J; Klei LR; Hubel NE; Zhang M; Schairer R; Maurer LM; Klei HB; Kang H; Concel VJ; Delekta PC; Dang EV; Mintz MA; Baens M; Cyster JG; Parameswaran N; Thome M; Lucas PC; McAllister-Lucas LM
    J Clin Invest; 2020 Feb; 130(2):1036-1051. PubMed ID: 31961340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.
    Hailfinger S; Nogai H; Pelzer C; Jaworski M; Cabalzar K; Charton JE; Guzzardi M; Décaillet C; Grau M; Dörken B; Lenz P; Lenz G; Thome M
    Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14596-601. PubMed ID: 21873235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
    Lyu MA; Rai D; Ahn KS; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Gandhi V; Rosenblum MG
    Neoplasia; 2010 May; 12(5):366-75. PubMed ID: 20454508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
    Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
    J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.
    Hathcock KS; Padilla-Nash HM; Camps J; Shin DM; Triner D; Shaffer AL; Maul RW; Steinberg SM; Gearhart PJ; Staudt LM; Morse HC; Ried T; Hodes RJ
    Blood; 2015 Nov; 126(20):2291-301. PubMed ID: 26400962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.
    Qu C; Liu Y; Kunkalla K; Singh RR; Blonska M; Lin X; Agarwal NK; Vega F
    Blood; 2013 Jun; 121(23):4718-28. PubMed ID: 23632891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
    Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
    Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
    Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
    Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
    Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
    Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.
    Ho L; Davis RE; Conne B; Chappuis R; Berczy M; Mhawech P; Staudt LM; Schwaller J
    Blood; 2005 Apr; 105(7):2891-9. PubMed ID: 15598810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.
    Bidère N; Ngo VN; Lee J; Collins C; Zheng L; Wan F; Davis RE; Lenz G; Anderson DE; Arnoult D; Vazquez A; Sakai K; Zhang J; Meng Z; Veenstra TD; Staudt LM; Lenardo MJ
    Nature; 2009 Mar; 458(7234):92-6. PubMed ID: 19118383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.
    Baens M; Bonsignore L; Somers R; Vanderheydt C; Weeks SD; Gunnarsson J; Nilsson E; Roth RG; Thome M; Marynen P
    PLoS One; 2014; 9(8):e103774. PubMed ID: 25105596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.
    Shah SB; Carlson CR; Lai K; Zhong Z; Marsico G; Lee KM; Félix Vélez NE; Abeles EB; Allam M; Hu T; Walter LD; Martin KE; Gandhi K; Butler SD; Puri R; McCleary-Wheeler AL; Tam W; Elemento O; Takata K; Steidl C; Scott DW; Fontan L; Ueno H; Cosgrove BD; Inghirami G; García AJ; Coskun AF; Koff JL; Melnick A; Singh A
    Nat Mater; 2023 Apr; 22(4):511-523. PubMed ID: 36928381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.
    Vicente-Dueñas C; Fontán L; Gonzalez-Herrero I; Romero-Camarero I; Segura V; Aznar MA; Alonso-Escudero E; Campos-Sanchez E; Ruiz-Roca L; Barajas-Diego M; Sagardoy A; Martinez-Ferrandis JI; Abollo-Jimenez F; Bertolo C; Peñuelas I; Garcia-Criado FJ; García-Cenador MB; Tousseyn T; Agirre X; Prosper F; Garcia-Bragado F; McPhail ED; Lossos IS; Du MQ; Flores T; Hernandez-Rivas JM; Gonzalez M; Salar A; Bellosillo B; Conde E; Siebert R; Sagaert X; Cobaleda C; Sanchez-Garcia I; Martinez-Climent JA
    Proc Natl Acad Sci U S A; 2012 Jun; 109(26):10534-9. PubMed ID: 22689981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.